Saby George, MD, FACP

PrintE-mail
Assistant Professor of Oncology
Roswell Park Cancer Institute

Profile

Areas of Expertise: 
Kidney Cancer
Prostate Cancer
Bladder Cancer

Research

Research Interests: 
Kidney cancer: My interests include clinical trials, novel drug development, mechanism of resistance formation to tyrosine kinase inhibitors, improving the response evaluation criteria and development of biomarkers.
Prostate cancer: Castrate refractory prostate cancer, high Gleason score disease, improving androgen deprivation therapy and biomarker development.

Background Information

Education and Training: 
Kottayam Medical College, Kerala, India
Residency: 
Wright State University, Dayton, OH
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
Experimental therapeutics-Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Medical Oncology-University of Texas Health Sciences Center at San Antonio, San Antonio, TX

Publications

Publications: 
  • George S, Brenner A, Sarantopoulos J, Bukowski RM. RANK ligand: Effects of inhibition. Current oncology reports 2010; 12(2):80-86
  • George S, Shah SN, Bukowski RM. Stable disease in renal cell carcinoma after using signal transduction inhibitors. Reviews on recent clinical trials 2010; 5(2):117-122
  • George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(9):1011-1018
  • George S, Choi K-S, Pili R, Kazim AL. The lipid metabolome of clear cell renal cell carcinoma (CCRCC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #10609
  • Kossoff E, Batty N, Ceacareanu AC, Attwood K, Miller D, Rabey J, Lee C, Ahmad A, Ebos JM, Schwaab T, George S, Pili R. Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e15042
  • Pili R, Shen L, George S, Hammers H, Sandecki A, Collins C, Espinoza-Delgado I, Carducci MA. Phase I/II study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #TPS4687
  • Von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad III EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane III JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(8):951-960